Preferred Label : cirrhosis of liver, nos;

Details


Main resources

You can consult :


https://www.cochrane.org/fr/CD011585/LIVER_la-rifaximine-pour-la-prevention-et-le-traitement-de-lencephalopathie-hepatique-chez-les-personnes
2023
United Kingdom
review of literature
french abstract
preventive treatment, nos
disease of liver, nos
disease
hepatic encephalopathy
persons
cirrhosis of liver, nos
Encephalopathy
Rifaximin
Cirrhosis
hepatic encephalopathy
liver cirrhosis

---
https://www.has-sante.fr/jcms/p_3215918/fr/indications-de-l-echographie-de-contraste-lors-de-suspicion-de-tumeur-hepatique-benigne-chez-l-adulte-sans-cirrhose-ni-cancer
2023
France
health technology assessment
Adult
Tumors
Tumors
adult
Tumors
liver cirrhosis
benign neoplasm of liver, nos
carcinoma, hepatocellular
Benin
suggestive of
Cancer
Tumors
ultrasonography
Tumors
Tumors
indicators and reagents
Adult
neoplasm, malignant
indication of
Tumors
benign neoplasms
cirrhosis of liver, nos
liver neoplasms
Tumors
Tumors
ultrasonography, nos
Tumors
Cirrhosis
Tumors
cancer of liver
adulthood
Tumors
Benign neoplasm

---
https://www.cochrane.org/fr/CD012358/LIVER_quels-sont-les-benefices-et-les-risques-des-stents-recouverts-par-rapport-aux-stents-nus
2023
United Kingdom
review of literature
french abstract
Intrahepatic Route of Administration
risks and benefits
cirrhosis of liver, nos
persons
albumin/globulin ratio
Macau
What Month is it
systemic administration
Cirrhosis
Shunt
Systemic Immunotherapy
People
liver cirrhosis
research report
Recovered from Adverse Event
risk assessment
Shunt Device
stents
Stent Device
Hazard Ratio
disease
shunt, nos

---
https://www.medg.fr/cirrhose-hepatique
2019
France
teaching material
scientific and technical information
liver cirrhosis
Cirrhosis
cirrhosis of liver, nos

---
https://medicalforum.ch/fr/detail/doi/fms.2018.08015/
2018
Switzerland
journal article
cirrhosis of liver, nos
liver cirrhosis
cirrhosis
Cirrhosis
fibrosis

---
http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-05-fra.php#mise_%C3%A0_jour
2016
false
false
false
Canada
French
pharmacovigilance note
socioeconomic factors
monograph
cirrhosis of liver, nos
patients
has patient
sectional
indicators
decompensation
administration of medication, nos
effective
drug interactions
disease of liver, nos
observation
drug monitoring
pharmacovigilance
dasabuvir
contraindication to
liver cirrhosis
risk
effect modifier, epidemiologic
drug interaction
hepatic failure, nos
positive
administration
hepatic insufficiency
medication adherence
cirrhosis
monograph
indicators and reagents
observation
drug monitoring
dasabuvir
organization and administration
fibrosis
sulfonamides
uracil

---
Nous contacter.
26/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.